A phase II trial of tiragolumab in combination with atezolizumab and bevacizumab in patients with previously treated, microsatellite stable, metastatic colorectal adenocarcinoma
The goal of this study is to learn if a new combination treatment is effective for patients with microsatellite stable, advanced colorectal cancer. The study treatment combines 3 drugs: atezolizumab, bevacizumab, and tiragolumab. The main questions the stu
Why this Research Matters
This is a phase II study investigating the efficacy and safety of a triple-combination immunotherapy regimen in patients diagnosed with microsatellite stable metastatic colorectal cancer (MSS mCRC), refractory to fluorouracil, oxaliplatin, and irinotecan c
Who can Participate
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study. https://clinicaltrials.gov/study/NCT06784947?term=NCT06
Study ID
Protocol Number: 24-0547
More information available at ClinicalTrials.gov: NCT06784947
Meet the Team
Principal Investigator